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A newly developed single quad mass spectrometry (MS) detector was coupled to a ultra-high perfor-
mance liquid chromatography (UPLC) system and implemented in the routine quality control (QC) and
impurity analysis of four therapeutic peptides, namely bleomycin sulfate, tyrothricin, vancomycin HCl
and bacitracin, which were selected given their multi-component drug nature and their closely struc-
turally related impurity proﬁles. The QC and impurity proﬁling results obtained using the ultra-high
performance liquid chromatography ultraviolet/mass spectrometry (UPLC-UV/MS) detection system
were analyzed against the results obtained using traditional high performance liquid chromatography-
ultraviolet detection (HPLC-UV) methods derived from pharmacopoeial methods. In general, the used
stationary phases of sub-2 mm particle (UPLC) technology resulted in lower limits of detection and higher
resolution separations, which resulted in more detected impurities and shorter overall run times con-
trasting the traditional HPLC columns. Moreover, online coupling with a single quad MS detector allowed
direct peak identiﬁcation of the main compounds as well as small impurities, hereby increasing the
information content without the need of reference standards.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past few decades, mass spectrometry (MS) has become
an essential tool in fundamental disease research [1–4]. Mass spec-
trometry-based proteomics, metabolomics, peptidomics, glycomics,
phosphoproteomics and lipidomics are used to quantitatively and
qualitatively differentiate protein, peptide, sugar and lipid structures
of patients and healthy volunteers, in order to identify new bio-
markers or seek treatment opportunities [5]. Due to the complexity of
these human samples, as well as the quest to obtain greater sensi-
tivity, a wide variety of high-end mass spectrometry instruments
have been developed in recent years. An excellent review written by
Domon and Aebersold provides a performance overview of different
types of MS used in proteomic ﬁeld. For example, triple quadrupole
instruments were used for quantiﬁcation of proteins and ultra-high
resolution Fourier transform ion cyclotron resonance (FT-ICR) for their
identiﬁcation [3]. MS has also been applied in drug development such
as drug metabolism studies [6,7]. The factors that limit the wide-
spread use of high-end MS instruments are high purchasing costs and
expensive maintenance. Furthermore, highly skilled operators for
method optimization and subsequent data interpretation are needed.
Factors like those mentioned above have limited the use of MSon and hosting by Elsevier B.V. All
University.
e Spiegeleer).in routine pharmaceutical quality control (QC) environments. The
performance demands on MS instrumentation in routine phar-
maceutical setting are less challenging than those in the “omics”-
ﬁeld, as matrix effects are less evident and drug concentrations are
much higher. However, simpliﬁed operation and maintenance
within a good manufacturing practice (GMP) environment are
paramount, which leads to the need for downsized and lower-end
MS systems. Recently, a number of small single quad MS detectors
that are directly compatible with the existing high performance
liquid chromatography (HPLC)/ultra-high performance liquid
chromatography (UPLC) equipment and software platforms used
in QC, have been developed and introduced into the pharmaceu-
tical setting [8–10]. The availability of these new MS detectors has
created the potential to bring routine use of MS to the QC la-
boratory and pharmaceutical QC to a higher level. The present
work considered a new ultra-high performance liquid chromato-
graphy ultraviolet/mass spectrometry detection (UPLC-UV/MS)
equipment set-up in relation to the traditional high performance
liquid chromatography-ultraviolet detection (HPLC-UV) set-up for
the QC and impurity proﬁling of complex therapeutic peptides.2. Materials and methods
2.1. Materials
Tyrothricin, bacitracin, propionic acid, sodium pentane sulfate,rights reserved. This is an open access article under the CC BY-NC-ND license
Table 1
Overview of selected peptides.
Name Major compoundsa Formula Molecular weightb Sample solventc Ph. Eur. concentrationc
Bleomycin sulfate Bleomycin A2 C55H84N17O21S3 1414.52 H2O Test solution: 0.5 mg/mLd
Bleomycin B2 C55H84N20O21S2 1424.56
Tyrothricin Gramicidin A1 C99H140N20O17 1881.07 15 volumes H2O Test solution: 1.0 mg/mL
Gramicidin A2 C100H142N20O17 1895.09 85 volumes MeOH Ref. solution B: 0.02 mg/mLd
Gramicidin C1 C97H139N19O18 1858.05
Gramicidin C2 C98H141N19O18 1872.07
Tyrocidin A C66H88N13O13 1270.66
Tyrocidin B C68H89N14O13 1309.67
Tyrocidin C C70H90N15O13 1348.68
Tyrocidin D C72H91N16O12 1371.70
Tyrocidin E C66H88N13O12 1254.67
Vancomycin HCl Vancomycin B C66H75Cl2N9O24 1447.43 10 volumes THF Test solution A: 2.0 mg/mL
70 volumes ACN Test solution B: 0.08 mg/mL
920 volumes H2O Test solution C: 0.002 mg/mLd
Bacitracin Bacitracin A C66H103N17O16S 1421.75 40 volumes ACN Test solution: 2.0 mg/mL
Bacitracin B1 C65H101N17O16S 1407.73 400 volumes H2O Ref. solution C: 0.01 mg/mLd
Bacitracin B2 C65H101N17O16S 1407.73 520 volumes MeOH
Bacitracin B3 C65H101N17O16S 1407.73
a As listed in Ph. Eur. monograph.
b Monoisotopic molecular weight.
c Based upon Ph. Eur. 8.0 monographs, buffer solution substituted with H2O.
d For disregard limit purposes.
Table 2
Chromatographic conditions of selected peptides (Ph. Eur.).










Bleomycin sulfate MeOH Pentanesulfonate buffer 100 1.2 Room 20 254
Tyrothricin 75 MeOH – 60 1.2 60 25 280
25 sulfate buffer
Vancomycin HCl 70 ACN 290 ACN 35 1 Room 20 280
10 THF 10 THF
920 triethylamine 700 triethylamine

































M. D’Hondt et al. / Journal of Pharmaceutical Analysis 6 (2016) 24–31 25sodium sulfate and triethylamine were bought from Sigma-Aldrich
(Diegem, Belgium), whereas vancomycin HCl was purchased from
Bufa (Ijsselstein, the Netherlands). These peptides were orderedwithout explicit pharmacopoeial quality requirements, in order to
increase the probability of containing related impurities. Bleomy-
cin sulfate was obtained from Sanoﬁ Aventis (Brussel, Belgium).
Acetonitrile, methanol and tetrahydrofuran of HPLC grade were
acquired from Fisher Scientiﬁc (Aalst, Belgium), whereas acetoni-
trile, methanol and triﬂuoroacetic acid (TFA) of UPLC grade were
bought from Biosolve (Valkenswaard, the Netherlands). Water was
puriﬁed using an Arium 611 puriﬁcation system (Sartorius, Gottin-
gen, Germany) yieldingZ18.2 MΩ cm quality water. Potassium
dihydrogen phosphate and ammonium sulfate were purchased from
Merck (Overijse, Belgium), whereas dipotassium hydrogen phos-
phate was obtained from Panreac Chimica (Barcelona, Spain).2.2. Peptide selection
Three different antimicrobial peptides, i.e., tyrothricin (cyclic
polypeptide), vancomycin HCl (glycopeptide), bacitracin (cyclic
polypeptide), and the chemotherapeutic peptide bleomycin sulfate
(glycopeptide) were selected as test compounds, given their
complex and multi-component drug nature and their closely
structurally related impurity proﬁles. An overview of the selected
peptides, as well as their major components and structural prop-
erties, is given in Table 1.
Fig. 1. Bleomycin sulfate (0.5 mg/mL) HPLC-UV (A) and UPLC-UV/MS (B) analysis with identiﬁcation of major compounds and method comparison. The MS1 spectra of the
main compounds bleomycin A2 and B2, as well as impurities bleomycin A5 and demethylbleomycin A2, are given.
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Peptide samples were analyzed using HPLC-UV method derived
from European Pharmacopoeia (Ph. Eur.), as well as by newly de-
veloped UPLC-UV/MS method [11–14]. As the latter also comprised
MS detection, peptide sample solutions were prepared by repla-
cing the buffer components with H2O, whilst maintaining the
same target concentrations as stipulated in the Ph. Eur. Details
regarding peptide concentrations and solvents used for the sam-
ples are given in Table 1.
2.4. Chromatography
The HPLC apparatus consisted of a Waters Alliance 2695 se-
parations module and a Waters 2996 Photodiode Array (PDA)
detector with Empower 2 software for data acquisition (all Waters,
Milford, MA, USA). Chromatographic analysis of the four selected
peptides was based upon the methods as described in the Ph. Eur.
[11–14]. Tyrothricin, vancomycin HCl and bleomycin sulfate were
analyzed with a Lichrospher 100 RP-18 (250 mm4 mm, 5 mm)
(Merck, Overijse, Belgium), whereas bacitracin was analyzed with
a Hypersil ODS (250 mm4 mm, 5 mm) (Thermo Scientiﬁc,Erembodegem-Aalst, Belgium). A brief overview of the chroma-
tographic conditions is given in Table 2.
The UPLC equipment consisted of a Waters UPLC Quaternary
Solvent Manager, a Waters ACQUITY Sample Manager, a Waters
Ultra Performance LC (UPLC) PDA, a Waters ACQUITY Isocratic
Solvent Manager and a Waters ACQUITY QDa detector (QDa)
which is a compact single quad mass detector equipped with an
electrospray ionization (ESI) interface. For data acquisition and
instrument control, the Empower 3 FR 2 software was used. The
ACQUITY UPLC CSH C18 column (100 mm2.1 mm, 1.7 mm) (Wa-
ters, Zellik, Belgium) was maintained at 40 °C [15]. Mobile phase A
consisted of a 95/5 H2O/ACNþ0.1% TFA, whilst mobile phase B
consisted of a 5/95 composition of the same solvents. Different
gradient methods were used for peptide analysis (Table 3). The
ﬂow rate was set at 0.5 mL/min and the injection volume was 2 mL.
A post-column 10/1 PDA/QDa split ratio was employed, together
with a post-column addition of 40/10/50 H2O/propionic acid/2-
propanol at a ﬂow rate of 0.35 mL/min to the portion going to the
QDa. This post-column addition neutralized the TFA ion suppres-
sion effect [16] and sustained a sufﬁcient ﬂow rate to the QDa
detector. The QDa was operated in an electrospray positive ion
mode by applying a voltage of 0.8 kV to the ESI capillary and the
Fig. 2. Tyrothricin (1 mg/mL) HPLC-UV (A) and UPLC-UV/MS (B) analysis with identiﬁcation of major compounds and method comparison. Exemplary MS1 spectra of main
compounds tyrocidin C and gramicidin C1, are given.
M. D’Hondt et al. / Journal of Pharmaceutical Analysis 6 (2016) 24–31 27cone voltage was set at 15 V. The desolvation temperature was set
at 600 °C. A full mass spectrum between m/z 100 and 1250 was
acquired at a sampling rate of 2.0 points/sec.
The HPLC and UPLC methods were compared based upon
(i) the system suitability tests (SST), i.e., resolution, peak to valley
ratio (p/v), signal-to-noise ratio (S/N) and symmetry factor (As),
listed in the Ph. Eur.; (ii) the quality limits of the active pharma-
ceutical ingredient (API); (iii) the limit of detection (LOD) based on
S/N ratio; (iv) the number of peaks detected above reporting
threshold (reported peaks); (v) the number of peaks (tentatively)
identiﬁed; and (vi) the total run time.3. Results
Chromatograms obtained from HPLC-UV and UPLC-UV/MS ana-
lysis of bleomycin sulfate are given in Fig. 1. Using the HPLC-UV
method, bleomycin A2 and B2 were identiﬁed by their high nor-
malized peak areas (62.79% and 34.05%) [11]. Impurity D (de-
methylbleomycin A2) was identiﬁed by its relative retention time
(RRT) to bleomycin A2, i.e., 1.5 to 2.5. Although this HPLC-UV methodadheres to the individual monograph SST (resolution between
bleomycin A2 and B2 is higher than 5; peak width at half height),
signiﬁcant tailing was observed, i.e., above the maximal value of
1.5 as given in the Ph. Eur. 2.2.46, and the amount of bleomycin B2
surpassed the limit stipulated in the Ph. Eur. This is an example of
how an averagely performing HPLC-UV QC method, combined with
inadequate integration, can result in a fals low quality conclusion.
Using the UPLC-UV/MS method, which resulted in a better chro-
matographic separation of all compounds as evidenced by the re-
duction in tailing of the major bleomycin compounds and increased
resolution with the present impurities, the amount of bleomycin B2
was determined to be 29.0%, thus complying with the Ph. Eur. limit.
Moreover, using MS detection, the identity of the bleomycin A2 (m/z
708.08 and 472.44; z¼2, 3) and B2 (m/z 713.52 and 476.06; z¼2, 3)
was conﬁrmed. Furthermore, two additional Ph. Eur.-listed im-
purities were identiﬁed by their mass spectra, i.e., bleomycinic acid
(m/z 657.34; z¼2) and bleomycin A5 (m/z 720.42 and 480.73; z¼2,
3). The identity of demethylbleomycin A2 (impurity D) was also
conﬁrmed by MS (m/z 701.04; z¼2). Finally, it was noted that the
total run time of the UPLC-UV/MS method was reduced to 20 min,
whereas the run time of HPLC-UV was 100 min.
Fig. 3. HPLC-UV (A) and UPLC-UV/MS (B) analysis of vancomycin HCl (2 mg/mL) with identiﬁcation of major compounds and method comparison. The MS1 spectra of the
main compound, Vancomycin B, and two exemplary impurity peaks are given.
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analysis of tyrothricin are given in Fig. 2. Due to the complex nature
of the tyrothricin sample that contains different tyrocidins and
gramicidins, formal identiﬁcation was not possible with the HPLC-
UV method without an additional analysis for retention time
matching to reference standards. Moreover, in the absence of cer-
tiﬁed reference materials, calculation of the SST (peak to valley ratio
between gramicidin A1 and A2) could not be performed to verify
whether the method was Ph. Eur. compliant. Alternatively, using the
UPLC-UV/MS method, tyrocidins A-D (m/z: 636.01, 655.67, 675.11
and 686.47, respectively; z¼2) and gramicidin A1, A2 and C1 (m/z:
941.65, 948.76 and 930.22, respectively; z¼2) were identiﬁed based
upon their MS spectra and the presence of Kþ adducts.
Chromatograms obtained from HPLC-UV and UPLC-UV/MS
analysis of vancomycin HCl are given in Fig. 3. Identiﬁcation of
vancomycin B using the traditional HPLC-UV method was done by
its high relative peak area, whereas aglucovancomycin B (Ph. Eur,
impurity C) was identiﬁed based upon its relative retention time to
vancomycin B [17]. Analysis of the same sample using the UPLC-
UV/MS method improved the resolution, resulting in the separa-
tion of more impurity peaks. Moreover, using the MS detection,
the majority of these impurity peaks could be tentativelyidentiﬁed based upon their MS1 spectra and the work was per-
formed by Diana et al. (Table 4) [17]. The mass spectra of two
vancomycin-related impurities, which were tentatively identiﬁed
as a demethylated impurity (peak 3) and aglucovancomycin B
(peak 13), are given in Fig. 3. Even though their individual im-
purity amount, relative to the main compound vancomycin B, was
well below 1%, i.e., 0.1% for peak 3 and 0.3% for peak 13, these mass
spectra could be used for immediate identiﬁcation purposes.
A similar observation was made for analysis of bacitracin by
UPLC-UV/MS. Conﬁrmation of the identity of the main com-
pounds, as well as tentative identiﬁcation of major impurity peaks
was done with reference to the previous MS research performed
by Govaerts et al. [18]. The mass spectra of the main compound
bacitracin A, as well as of two small impurities, i.e., bacitracin E
(1.5% relative to bacitracin A) and bacitracin H (1.7% relative to
bacitracin A), are given in Fig. 4 and were positively used for
identiﬁcation purposes. The total run time of the UPLC-UV/MS
method was also drastically reduced compared with the HPLC
method, i.e., 16.8 min vs. 75 min.
A comparison between the performances of the traditional
HPLC-UV and new UPLC-UV/MS method for the QC analysis of
bleomycin sulfate, vancomycin HCl and bacitracin is given in Fig. 5.
Fig. 4. HPLC-UV (A) and UPLC-UV/MS (B) analysis of bacitracin (2 mg/mL) with identiﬁ
compound, bacitracin A, and two exemplary impurity peaks, are given.
Table 4
Tentatively identiﬁed vancomycin HCl related impurities.
# RT (min) m/z Identiﬁcation
1 1.134 661.24 Oxidized desvancosaminylvancomycin,
Demethylleucylvancomycin B
2 5.028 734.78 Crystalline degradation product (demethylated),
Deamidated vancomycin B (demethylated),
N-demethylvancomycin B
3 5.095 718.40 Crystalline degradation product (demethylated),
Deamidated vancomycin B (demethylated)
4 5.209 725.51 Oxidized vancomycin B (demethylated),
Crystalline degradation product major,
Crystalline degradation product minor
5 5.318 717.77 Crystalline degradation product (demethylated),
Deamidated vancomycin B (demethylated),
N-demethylvancomycin B
6 5.950 718.47 Crystalline degradation product (demethylated),
Deamidated vancomycin B (demethylated)
7 6.009 724.95 Crystalline degradation product major,
Crystalline degradation product minor
8 6.098 725.51 Oxidized vancomycin B (demethylated)
9 6.302 724.95 Crystalline degradation product major
Crystalline degradation product minor
10 6.369 725.44 Vancomycin B
11 6.518 725.92 Oxidized vancomycin B (demethylated)
12 6.707 725.58 Oxidized vancomycin B (demethylated)
13 12.694 1143.48 Aglucovancomycin B
M. D’Hondt et al. / Journal of Pharmaceutical Analysis 6 (2016) 24–31 29As tyrothricin components could not be identiﬁed using the HPLC-
UV method, performance comparison could not be made.4. Discussion
The advantages of sub-2 mm chromatography (UPLC) over tra-
ditional HPLC chromatography for analysis of pharmaceutical
compounds have already been extensively documented [19–23].
The use of smaller particle size with an optimized LC system gives
improved efﬁciency, resulting in faster and higher resolution se-
parations than those of traditional LC systems with column par-
ticle sizes in the 3–10 mm range. For the transfer of a method from
traditional HPLC to UPLC (and vice versa), guidance about the
adjustment of column size, injection volume, ﬂow rate and time
program for gradient elution are available [24]. However, this was
not the main objective of this study. The goal of this study was to
inspire pharmaceutical analysts to implement new technologies in
method development. Currently, most LC-based quality control
methods for APIs listed in the Ph. Eur. generally still utilize sta-
tionary phases with a particle size of 3–10 mm. Small variations in
particle size are permitted for isocratic methods, i.e., reduction of
50% in particle size, whereas no alteration in particle size is al-
lowed with gradient elutions [25]. As a result, the use of UPLCcation of major compounds and method comparison. The MS1 spectra of a main
Fig. 5. Relative performance comparison between UPLC-UV/MS and HPLC-UV method for bleomycin sulfate, vancomycin HCl and bacitracin QC analysis. HPLC-UV per-
formance was set at 100%.
M. D’Hondt et al. / Journal of Pharmaceutical Analysis 6 (2016) 24–3130converting existing API quality control methods in Ph. Eur. into
faster and more efﬁcient sub-2 mm methods is currently not al-
lowed without validation. Hence, simple transferring HPLC–UPLC
methods in pharmaceutical QC method validation is currently not
allowed. Moreover, it is emphasized that when a method is
changed, the corresponding acceptance limits are also to be re-
considered [26]. However, newly developed quality control
methods have already used this sub-2 mm stationary phase as
evidenced by the related substance methods for quetiapine fu-
marate and nevirapine hemihydrate [27,28]. Moreover, the revised
Ph. Eur. 8.3 general chapter 2.2.29 liquid chromatography covers
sub-2 mm particle technology [29].
Although MS is listed as an analytical technique in the Ph. Eur.
[30], its use in the quality control of APIs is currently limited to a few
cases, e.g. detection of impurity B of oseltamivir phosphate, detection
of impurity F of imatinib mesilate, and determination of the inter-
feron β-1a isoform distribution [31–33]. However, as the newly de-
veloped single quad MS detector is smaller, cheaper and easily used,
it is expected that its application will increase exponentially. Coupled
to UPLC separation module, it adequately answers the current shift in
QC emphasis from API assay towards impurity proﬁling [34,35].
This study has demonstrated the applicability of identifying
related impurities and/or multiple active components in complex
API samples using a single quad MS detector. The current equip-
ment set-up, using a post-column split, coupled with post-column
addition of a propionic acid containing solvent, even permits the
use of TFA to improve chromatographic peak shape [36], without
compromising the MS detection too much. As liquid chromato-
graphic methods with volatile buffers often show inferior chro-
matographic separation compared with analogous methods with
non-volatile buffers [37], the use of the anionic ion-pairing reagent
TFA for peptide separation is important to counterbalance the loss
in chromatographic performance. As expected, resolution and LODwere improved by the use of sub-2 mm column technology and the
overall run time was signiﬁcantly reduced, when compared with
traditional 3–10 mm HPLC methods listed.5. Conclusion
A newly developed, single quad MS detector was coupled to a
UPLC separation module and used in routine quality control analysis
of bleomycin sulfate, tyrothricin, vancomycin HCl and bacitracin
peptide APIs. The results were compared with the results obtained
by traditional HPLC-UV methods which were based upon the Ph. Eur.
As expected, the UPLC separation resulted in a higher resolution and
a lower limit of detection, as well as a signiﬁcant reduction in run
time. Furthermore, MS detector may enable to directly identify im-
purities or components even at low levels without the need of re-
ference standards. Currently, MS is only sparsely applied in the Ph.
Eur. However, recent technical advances deliver ﬁt for using single
quad MS detectors to the pharmaceutical ﬁeld, and its applications in
QC analysis are expected to rise in the near future.Acknowledgments
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